Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

2.1 Nivolumab (Opdivo, Bristol Myers Squibb) 'in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD‑L1 expression ≥ 1%'.

2.2 The dosage schedule is available in the summary of product characteristics for nivolumab.

2.3 The list price is £1,097 for a 100-mg vial (excluding VAT; BNF online accessed September 2022). The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.